Find a Clinical Trial
Is a clinical trial right for you? Search our database to find studies for which you may be eligible.
A Phase II, Randomized, Open-label Study of Onvansertib in Combination with FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-line Treatment of Metastatic Colorectal Cancer in Patients with a KRAS or NRAS Mutation
Study Type: Treatment
Phase: II
NCTID: NCT06106308
Principal Investigator:
Anup Kasi
Phase I/II, Double-Blind, Placebo-Controlled, Dose Escalation and Expansion Study of ALVR106 for the Treatment of High-Risk Patients With Respiratory Viral Infections After Hematopoietic Cell Transplant
Study Type: Treatment
Phase: I/II
NCTID: NCT04933968
Principal Investigator:
Rajat Bansal
A Phase I/II, Dose-Exploration and Dose-Expansion Study Evaluating the Safety and Efficacy of Multiplex Base-Edited, Allogenic Anti-CD7 Car-T Cells BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia T-ALL or T-Cell Lymphoblastic Lymphoma T-LL
Study Type: Treatment
Phase: I/II
NCTID: NCT05885464
Principal Investigator:
Forat Lutfi
A Phase I Dose Escalation and Expanded Cohort Study of Pf-06821497 in the Treatment of Adult Patients with Relapsed/Refractory Small Cell Lung Cancer SCLC, Castration Resistant Prostate Cancer CRPC and Follicular Lymphoma FL
Staying Strong and Healthy during Androgen Deprivation Therapy for Latino Men
Study Type: Supportive Care
Phase: N/A
NCTID: NCT02969577
Principal Investigator:
A Phase Ib/IIa Trial Of CEND?1 In Combination With Neoadjuvant FOLFIRINOX Based Therapies In Pancreatic, Colon And Appendiceal Cancers CENDIFOX
Study Type: Treatment
Phase: I/II
NCTID: NCT05121038
Principal Investigator:
Anup Kasi
A Phase 2 Open-label Extension Study for Subjects with Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study ICON study number: 0798/0661
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with 1 cm Residual Invasive Cancer or Positive Lymph Nodes ypN1mi, ypN1-3 After Neoadjuvant Chemotherapy
A Randomized Phase II Study of INC280 capmatinib plus Osimertinib with or without Ramucirumab in Participants with EGFR-Mutant, METAmplified Stage IV or Recurrent Non-Small Cell Lung Cancer Lung-MAP Sub-Study
A Phase IIIB, Multicenter, Open-label, PCI-32765 Ibrutinib Long-term Extension Study
Study Type: Treatment
Phase: III
NCTID: NCT01804686
Principal Investigator:
Marc Hoffmann